JEOL Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

In Q1 of FY2027, the Company’s operating results fell into the red as a change in business composition resulting from the transfer of the Medical Equipment Business coincided with declining revenue in its core businesses. Revenue was ¥244.7B (-39.1% YoY), Operating Income was ¥-19.6B (deteriorating from ¥57.9B in the same period of the previous year), Ordinary Income was ¥-13.6B (same), and Net Income was ¥-17.1B. Although the gross margin remained high at 48.1%, the Company was unable to absorb SG&A expenses (56.1% of revenue) amid declining revenue, with the reversal of operating leverage being the primary cause of the loss.

Factors Affecting Results

【Revenue】Revenue was ¥244.7B, down -39.1% YoY. The Scientific Instruments and Metrology Business generated ¥194.9B (-8.8% YoY), while the Industrial Equipment Business generated ¥49.8B (-65.6% YoY), with both segments posting revenue declines. The decline in the Industrial Equipment Business was particularly pronounced. By region, revenue from China plunged from ¥137.0B to ¥29.7B, becoming one of the primary causes of the consolidated revenue decline. In addition, the Medical Equipment Business was transferred at the beginning of the current period and excluded from the reported segments; therefore, the year-on-year comparison includes the impact of the portfolio change.

【Profit and Loss】Although the gross margin remained at 48.1%, SG&A expenses of ¥137.3B (56.1% of revenue) exceeded gross profit of ¥117.7B, resulting in Operating Income of ¥-19.6B. Corporate expenses increased from ¥17.1B in the previous year to ¥19.1B, expanding the consolidated deficit relative to the combined segment loss of ¥-0.5B. Special income, including a gain on the transfer of a business of ¥1.6B, reduced the loss before tax to ¥-12.0B; however, recognition of income taxes and other taxes of ¥5.1B expanded the net loss to ¥-17.1B. In conclusion, the Company experienced declines in both revenue and profit.

Segment Analysis

The Scientific Instruments and Metrology Business recorded Revenue of ¥194.9B (-8.8% YoY) and an Operating Loss of ¥2.7B, with the deficit remaining broadly flat from the previous year’s loss in the ¥2.7B range. Although the Industrial Equipment Business experienced a sharp decline in Revenue to ¥49.8B (-65.6% YoY), it secured Operating Income of ¥2.2B and remained profitable. However, this represents a substantial contraction from the previous year’s profit level of ¥72.2B (Profit YoY -96.9%), indicating a high dependence on individual projects. Corporate expenses reached ¥19.1B, exceeding the combined ¥0.5B loss of the two segments and driving the consolidated deficit.

Key Financial Indicators

【Profitability】The Operating Margin was -8.0% and the Net Profit Margin was -7.0%, both significantly deteriorating from the same period of the previous year (Operating Margin of approximately 14.4% and Net Profit Margin of approximately 11.6%). The gross margin remained at 48.1%, indicating that the primary cause of the deterioration in profitability was reduced capacity to absorb SG&A expenses rather than cost pressures.【Cash Flow Quality】Accounts receivable of ¥360.8B and work in process of ¥560.1B represent substantial accumulation of working capital, suggesting that funds remain tied up during the production and collection stages.【Investment Efficiency】ROE was -1.2%, with slower asset turnover and the recognition of losses weighing on capital efficiency. R&D expenses were ¥25.9B, equivalent to 10.6% of Revenue, indicating that the level of technology investment was maintained even amid declining revenue.【Financial Soundness】The Equity Ratio was 62.3% (up from 59.9% in the previous year), while cash and deposits of ¥322.4B substantially exceeded short-term borrowings of ¥40.0B, leaving the financial base at a conservative level.

Cash Flow Analysis

Although detailed disclosures of the cash flow statement are not available, the balance sheet trends provide insight into fund movements. Cash and deposits were ¥322.4B, down from ¥389.5B in the previous year. Meanwhile, accounts receivable declined from ¥505.0B in the previous year to ¥360.8B, while work in process increased from ¥534.9B to ¥560.1B, indicating that funds remain tied up during production. Contract liabilities (advances received) increased from ¥297.7B to ¥348.4B, providing a financial buffer through advance payments from customers. Net assets declined from ¥1449.0B to ¥1408.3B, with recognition of the net loss contributing to the reduction in capital.

Quality of Earnings

Against an Operating Loss of ¥19.6B, non-operating income of ¥7.2B—including dividend income of ¥1.5B, foreign exchange gains of ¥0.9B, and equity-method income of ¥2.0B—partially offset the loss, leaving an Ordinary Loss of ¥13.6B. Most of the special income of ¥1.6B was attributable to a gain on the transfer of a business, a temporary factor that reduced the loss before tax to ¥11.98B. Excluding this temporary gain, the underlying loss would have been larger, making the impairment of recurring earnings power the fundamental issue. Income taxes and other taxes of ¥5.1B were incurred despite the recognition of a loss, causing the Net Loss to expand beyond the loss before tax to ¥17.1B. Comprehensive income was ¥-2.0B, broadly comparable to Net Income, with other comprehensive income items such as valuation differences on securities and foreign currency translation adjustments providing a certain degree of cushioning.

Earnings Forecast and Guidance

The full-year Company forecast calls for Revenue of ¥1640.0B (-8.6% YoY), Operating Income of ¥265.0B (+1.9% YoY), and Ordinary Income of ¥262.0B (-8.4% YoY), with no revisions to the forecast. Q1 progress rates were 14.9% for Revenue, while both Operating Income and Net Income were negative, substantially below the standard quarterly progress rate of approximately 25%. Although the plan may be weighted toward the second half of the fiscal year, achieving full-year profitability will require a recovery in revenue, absorption of corporate expenses, and normalization of production and order intake in the Industrial Equipment Business.

Shareholder Returns

The Company’s forecast annual dividend is ¥132.00 per share, with no revision. Based on forecast EPS of ¥432.64, the forecast Payout Ratio is approximately 30.5%, which appears to be within a sustainable range relative to historical Payout Ratio levels. However, the Company recorded a Net Loss of ¥17.1B in Q1, making achievement of the full-year earnings plan the basis for supporting the dividend funding. The financial base, including cash and deposits of ¥322.4B and an Equity Ratio of 62.3%, supports the capacity to pay dividends in the short term.

Risk Factors

1. Demand and project recognition volatility: Revenue declined -39.1% YoY, and the full-year Revenue progress rate was only 14.9%. For high-value, long-lead-time projects in the Scientific Instruments and Metrology Business and the Industrial Equipment Business, fluctuations in customers’ investment decisions and acceptance timing can materially affect quarterly results.

2. Overseas market demand and foreign exchange volatility: Revenue from China plunged from ¥137.0B to ¥29.7B, and fluctuations in overseas demand have a significant impact on the growth rate. Although a foreign exchange gain of ¥0.9B was recorded, a reversal in the direction of exchange rates could affect non-operating income and expenses.

3. Prolonged production and acceptance lead times: Work in process of ¥560.1B accounts for the majority of inventories, and working capital remains high when combined with accounts receivable of ¥360.8B. Prolonged production and acceptance processes could affect the speed of cash conversion during a recovery in earnings.

Industry Benchmark (For Reference; Compiled by the Company)

Key Takeaways from the Earnings Results

1. The gross margin remained at 48.1%, at a level comparable to the previous year, indicating that the primary cause of the operating deficit was reduced capacity to absorb SG&A and corporate expenses rather than the cost structure.

2. While the Industrial Equipment Business remained profitable despite a sharp decline in revenue, the Scientific Instruments and Metrology Business continued to post a loss despite its relatively smaller revenue decline, clearly highlighting the differences in the earnings structures of the respective businesses.

3. Q1 progress rates against the full-year forecast were below standard levels for both revenue and profit. The degree to which revenue recovers and corporate expenses are absorbed in the second half will be a key point in assessing achievement of the full-year plan.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,395–¥3,599 at ±1% in the Cost of Equity, and ¥3,480–¥3,518 at ±0.1 in ω.

Note:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these are not forecasts of the market share price or recommendations of any specific investment action, and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a sharply weak start, with revenue down 39.1% year on year to ¥24.47bn and an operating loss of ¥1.96bn versus a ¥5.79bn operating profit a year earlier. The reported revenue decline includes the absence of the medical-equipment business, which was transferred at the start of the fiscal year, so the consolidated year-on-year comparison is not fully like-for-like. Nevertheless, the continuing Industrial Equipment business also deteriorated materially, with revenue falling 65.6% to ¥4.98bn and segment profit declining from ¥7.18bn to ¥0.22bn. Scientific and Measuring Instruments revenue declined a more moderate 8.8% to ¥19.49bn. That segment remained loss-making at ¥0.27bn, although its loss narrowed from ¥0.38bn in the prior-year quarter. Gross margin held up comparatively well at 48.1%, as gross profit fell 39.5%, broadly in line with revenue. The primary earnings pressure was therefore insufficient sales absorption of the cost base rather than a major gross-margin collapse. SG&A rose 0.5% year on year to ¥13.73bn while revenue contracted 39.1%, creating severe negative operating leverage. Corporate and unallocated costs increased to ¥1.91bn from ¥1.71bn, further deepening the consolidated operating loss. Net loss attributable to owners was ¥1.71bn, compared with prior-year profit of ¥4.67bn, and basic EPS was negative ¥35.12. Non-operating income of ¥0.72bn, including ¥0.15bn of dividend income and ¥0.09bn of foreign-exchange gains, partly offset the operating loss but did not restore profitability. A ¥0.16bn gain on transfer of business supported pre-tax results, meaning the underlying operating outcome was weaker than the reported pre-tax loss alone suggests. The tax expense of ¥0.51bn despite a pre-tax loss widened the net loss and resulted in a negative effective tax rate of 42.7%. The balance sheet remains conservatively funded, with a 226.7% current ratio, 0.61x debt-to-equity and cash equal to 8.06x short-term loans. However, long production cycles are a central operational concern: work in process was ¥56.02bn, 71.0% of total inventory categories, and construction in progress was ¥13.74bn, or 35.9% of PPE. Management's full-year guidance calls for ¥164.0bn of revenue and ¥26.5bn of operating income, requiring a substantial recovery after Q1 revenue progress of 14.9% and an operating loss. The investment focus is consequently on evidence of Industrial Equipment demand recovery, conversion of WIP into shipments and cash, and containment of overhead while the portfolio adjusts following the medical-business transfer.

Profitability Analysis

Annualized DuPont ROE was -4.9%, comprising a -7.0% net profit margin, 0.433x asset turnover and 1.61x financial leverage. The net-margin reversal was the decisive factor in the negative ROE: Q1 moved from ¥4.67bn of net profit in the prior year to a ¥1.71bn loss, while leverage remained moderate rather than aggressive. Annualized asset turnover of 0.433x also reflects a low Q1 revenue run-rate relative to the ¥226.16bn asset base. Gross margin was 48.1%, indicating that pricing and product mix at the gross-profit level were relatively resilient despite the sales decline. In contrast, operating margin deteriorated from 14.4% in the prior-year quarter to -8.0%, a 2,240bp compression. SG&A was ¥13.73bn, up 0.5% year on year, versus a ¥15.68bn revenue reduction, demonstrating pronounced negative operating leverage. R&D expense declined 17.5% to ¥2.59bn but still represented 10.6% of revenue, maintaining a meaningful technology-investment commitment during the downturn. Scientific and Measuring Instruments was the larger continuing business by revenue at ¥19.49bn, but remained a ¥0.27bn segment loss. Industrial Equipment produced only ¥4.98bn of revenue but remained modestly profitable at ¥0.22bn; its 4.4% segment margin was far below the prior-year quarter's 49.7%, indicating the greatest operational deterioration. Unallocated corporate costs rose to ¥1.91bn and exceeded the combined segment loss of ¥0.05bn, making central-cost absorption an additional profitability issue. The quality alert for low operating efficiency is warranted: the -8.0% EBIT margin is well below the 5% concern threshold. The reported annualized ROIC of -6.5% is likewise a material capital-efficiency concern because operating losses are being generated against a sizeable invested asset base. The 0.61 interest-burden ratio is mathematically affected by negative EBIT and should not be interpreted as a normal positive-profit interest burden; economically, interest expense was only ¥0.89bn, while net non-operating income partly mitigated the operating loss. A sustained margin recovery depends on restoring shipment volumes, particularly in Industrial Equipment, and reducing the mismatch between the current revenue base and fixed SG&A.

Growth Assessment

Reported revenue fell 39.1% to ¥24.47bn, reflecting both portfolio change from the medical-equipment business transfer and weaker revenue in the two continuing segments. Continuing Scientific and Measuring Instruments revenue declined 8.8% to ¥19.49bn, with regional growth in the Americas to ¥5.97bn partly offset by declines in China to ¥2.77bn and Japan to ¥5.13bn. Industrial Equipment revenue fell 65.6% to ¥4.98bn, with China particularly weak at ¥0.20bn compared with ¥8.12bn in the prior-year quarter. The regional mix therefore shifted away from China, whose consolidated revenue contribution fell from ¥13.70bn to ¥2.97bn. The current Q1 revenue represents 14.9% of the ¥164.0bn full-year sales forecast, 10.1 percentage points below the standard 25% Q1 progress rate. Q1 operating income progress is -7.4% of the ¥26.5bn full-year forecast, 32.4 percentage points below the standard pace, requiring a marked second-half earnings recovery. Full-year guidance assumes revenue declines 8.6% year on year but operating income rises 1.9%, which embeds significant margin normalization. The absence of a forecast revision indicates management is maintaining this recovery expectation. Revenue sustainability will be determined by whether the ¥56.02bn WIP balance converts into completed shipments without further delays, rework or margin concessions. R&D spending equal to 10.6% of Q1 revenue supports technological competitiveness, but it also limits near-term flexibility in the cost base. The ¥0.16bn gain on transfer of business is non-recurring and should not be treated as support for recurring earnings momentum.

Financial Health

Liquidity is strong on reported balance-sheet measures, with current assets of ¥154.03bn against current liabilities of ¥67.94bn, producing a 226.7% current ratio. The 198.5% quick ratio indicates that liquidity is not solely reliant on inventories. Cash and deposits of ¥32.24bn cover short-term loans of ¥4.00bn by 8.06x, and working capital was ¥86.10bn. Interest-bearing debt totaled ¥11.51bn, equivalent to 0.61x equity, while debt-to-capital was only 7.6%; neither the current ratio nor D/E triggers a conventional liquidity or leverage warning. Short-term loans declined ¥10.00bn, or 71.4%, year on year to ¥4.00bn, materially reducing refinancing pressure. Long-term loans were ¥7.51bn, so the debt maturity profile is not heavily concentrated in short-term borrowings. The reduction in short-term loans coincided with a ¥6.71bn decline in cash and a ¥14.43bn reduction in trade receivables, while total assets declined ¥15.86bn. Accounts receivable declined 28.6% to ¥36.08bn, which improves the absolute receivables exposure, although annualized DSO remains elevated at 135 days because of the weak Q1 revenue run-rate. Contract liabilities increased to ¥34.84bn from ¥29.77bn, providing a meaningful source of customer-funded working capital and mitigating part of the production-cycle funding burden. Total equity declined ¥4.07bn year on year to ¥140.83bn, principally reflecting lower retained earnings, but the capital adequacy ratio improved to 62.3% from 59.9% as assets contracted more than equity. Goodwill was only ¥0.75bn, equal to 0.5% of equity and 0.3% of assets, so the balance sheet has minimal dependence on acquired goodwill values. Asset-retirement obligations of ¥0.38bn equal less than 1% of liabilities, indicating limited identified environmental-retirement exposure. The debt-service alert requires monitoring because interest coverage was -22.03x: the root cause is negative EBIT, not an excessive nominal debt balance; the impact is that operating earnings currently do not cover interest expense, even though liquidity and leverage headroom remain sound. The high-interest-burden alert similarly reflects loss-period arithmetic, with EBT/EBIT at 0.61x, while the ¥0.89bn interest expense itself is modest relative to cash and debt capacity.

Notable B/S Changes

Short-term loans: -¥10.00bn (-71.4%) to ¥4.00bn - materially lowers short-term refinancing dependence and supports the strong liquidity profile. Accounts receivable: -¥14.43bn (-28.6%) to ¥36.08bn - reduces absolute customer-credit exposure, although annualized DSO remains elevated because Q1 revenue was weak. Raw materials: -¥1.26bn (-25.7%) to ¥3.64bn - inventory composition shifted further toward work in process rather than input materials. Software: +¥2.60bn (+379.3%) to ¥3.28bn - indicates a marked increase in capitalized software assets and raises the importance of future utilization and amortization returns. Work in process: +¥2.67bn (+5.0%) to ¥56.02bn - the absolute WIP build is significant against declining revenue and is central to production-cycle and cash-conversion risk. Construction in progress: +¥0.96bn (+7.5%) to ¥13.74bn, or 35.9% of PPE - a large share of the fixed-asset base remains under development, requiring timely completion and utilization.

Cash Flow Quality

The current operating result does not demonstrate cash earnings conversion because net income was a ¥1.71bn loss and the production cycle remains exceptionally long. Annualized DSO of 135 days is above the 60-day warning threshold; the root cause is a ¥36.08bn receivable balance relative to the depressed Q1 revenue run-rate. Its impact is slower cash realization and greater exposure to shipment timing and customer collection risk, although receivables were down ¥14.43bn year on year. Inventory composition is the more significant concern: WIP was ¥56.02bn, representing 71.0% of total inventory categories, well above the 40% warning threshold. This high WIP ratio points to prolonged manufacturing throughput, project execution timing or delayed completion risk and raises the possibility that margins and cash conversion will remain pressured if projects do not ship on schedule. The quality alert's annualized DIO of 567 days and cash conversion cycle of 638 days capture this WIP-heavy production cycle and are far above manufacturing benchmarks. Separately, the finished-goods inventory balance was ¥19.20bn, which corresponds to an annualized 138 days relative to Q1 cost of sales and is also above the 60-day benchmark. The two inventory-day measures reinforce the same conclusion: both production-stage and completed-goods capital are elevated relative to the current sales rate. Construction in progress was ¥13.74bn, or 35.9% of PPE, exceeding the 20% high-CIP warning level; this signals a substantial investment pipeline but also raises execution, commissioning-delay and return-on-investment risk. Contract liabilities of ¥34.84bn provide partial customer pre-funding and help offset working-capital strain. Recurring operating performance was weak, while the ¥0.16bn gain on transfer of business was non-recurring and should be excluded from assessments of normalized cash-generating capacity.

Dividend Sustainability

Management forecasts a full-year dividend of ¥132 per share and full-year EPS of ¥432.64, implying a forecast dividend payout ratio of approximately 30.5%. On the forecast basis, this is below the 60% sustainability benchmark and is supported by the company's low 7.6% debt-to-capital ratio and substantial liquidity. Q1 EPS was negative ¥35.12 because of the ¥1.71bn net loss, so interim earnings did not cover the annualized dividend commitment at this stage. Dividend sustainability therefore depends on delivery of the full-year earnings recovery rather than Q1 profitability. The forecast requires operating income of ¥26.5bn after a Q1 operating loss of ¥1.96bn, making earnings execution the key variable. The medical-business transfer and associated ¥0.16bn transfer gain should not be viewed as recurring funding for dividends. The balance-sheet position provides flexibility, but preservation of dividend coverage should be assessed against future operating cash conversion from WIP and receivables.

Risk Assessment

Business risks include Industrial Equipment demand and execution risk: revenue fell 65.6% year on year to ¥4.98bn and segment profit dropped from ¥7.18bn to ¥0.22bn. The sharp decline in China revenue to ¥0.20bn from ¥8.12bn is a particularly high-impact regional risk., Portfolio-transition risk: the medical-equipment business transfer changes the revenue base and limits direct comparability with the prior-year consolidated quarter. Realizing the forecast profit recovery requires successful reallocation of overhead following the divestiture., Manufacturing throughput risk: WIP of ¥56.02bn, equal to 71.0% of inventory categories, indicates a potential production bottleneck or extended project completion cycle. This is high likelihood and high impact because delayed conversion directly affects revenue, cash generation and inventory valuation., Customer and geographic concentration risk: the sharp fall in China sales illustrates sensitivity to regional capital-spending conditions, policy changes, trade restrictions and local competitive dynamics., Technology and product-cycle risk: R&D remained 10.6% of revenue, requiring commercialization returns despite weak near-term revenue absorption..

Financial risks include Loss-period debt-service risk: interest coverage was -22.03x because EBIT was negative ¥1.96bn. The root cause is operating loss rather than excessive leverage, but sustained losses would erode debt-service capacity., Working-capital risk: annualized DSO of 135 days, DIO measures of 567 days for WIP-heavy inventories and 138 days for finished goods, and a 638-day CCC indicate a large cash commitment relative to the current revenue rate., Capital-investment execution risk: construction in progress of ¥13.74bn, or 35.9% of PPE, may require further funding and carries commissioning and utilization risk., Tax volatility risk: a ¥0.51bn tax expense on a ¥1.20bn pre-tax loss produced a -42.7% effective tax rate and amplified the net loss., Currency risk: Q1 included ¥0.09bn of foreign-exchange gains, while overseas sales remain material; exchange-rate movements can affect both demand and reported earnings..

Key concerns include The low operating-efficiency alert is justified by the -8.0% EBIT margin, following a 2,240bp year-on-year operating-margin contraction., The capital-efficiency alert is justified by annualized ROIC of -6.5% and annualized ROE of -4.9%; losses are being earned on a large operating asset base., The high-interest-burden alert, with EBT/EBIT of 0.61x, is distorted by negative EBIT but still highlights that earnings have insufficient operating coverage for financing costs., The high receivables-days, high inventory-days, long-CCC and high-WIP alerts collectively indicate that recovery in accounting earnings must be validated by shipment and cash conversion., The high-CIP alert indicates that a sizeable portion of the fixed-asset base is not yet in service, increasing the importance of execution discipline and future utilization..

Investment Implications

Key takeaways include Gross margin resilience at 48.1% suggests the Q1 loss was principally a volume and fixed-cost absorption problem rather than broad gross-margin deterioration., Industrial Equipment is the main source of the year-on-year earnings collapse, while Scientific and Measuring Instruments showed a smaller revenue decline and a modestly narrower segment loss., The balance sheet is a relative strength, with 62.3% capital adequacy, 226.7% current ratio, 0.61x D/E and only ¥11.51bn of interest-bearing debt., High WIP, extended working-capital metrics and elevated CIP make operational conversion and project execution more important than balance-sheet solvency in the near term., Full-year guidance embeds a substantial back-end recovery, as Q1 sales and operating-profit progress were materially below standard seasonal progress..

Metrics to watch include Industrial Equipment revenue and segment margin, particularly China-related demand, Scientific and Measuring Instruments return to segment profitability, Quarterly SG&A relative to revenue and unallocated corporate costs, WIP conversion, finished-goods inventory levels, annualized DSO and cash conversion cycle, Construction-in-progress commissioning, utilization and associated returns, Progress toward ¥164.0bn revenue and ¥26.5bn operating-income guidance, Interest coverage as EBIT returns to positive territory.

Regarding relative positioning, Japan Electron retains a stronger-than-average liquidity and leverage profile for a manufacturer in a cyclical downturn, with negligible goodwill exposure and substantial customer contract liabilities. Its relative weakness is operational capital efficiency: negative margins, very long production-cycle indicators and elevated CIP contrast with a balance sheet that otherwise has considerable capacity to withstand near-term volatility.